Tuesday November 24 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

TranXenoGen

TranXenoGen is developing transgenic technologiesfor the production of transgenic animals, including

a non-viral method for the transfection of large transgenes

into chicken eggs (Direct-Egg Transfection). The goal is

transgenic chickens that express the recombinant protein

in the albumin fraction of their eggs.



TranXenoGen is also developing a technology (Gene-Testes

Transfection), designed to be applicable in many species of

animals. The technology targets transfection of a transgene

into the male animal in such a way that the male animal will

produce transgenic sperm. Consequently, the male can be

easily bred to generate transgenic animals.





TranXenoGen’s R&D projects also include:





Utilizing avian stem cells to improve the flexibility and

effectiveness of the transgenic chicken platform.





Developing of an in-licensed novel human protein,

anti-neoplastic urinary protein, “ANUP”, from Antitumor

Research Products. ANUP is believed to be an anti-

cancer protein, which is effective in treating cervical and

other cancers. TranXenoGen is currently in early stage

development and in-vitro testing of the product. If

successful, future development in animal models and

preclinical testing will commence.


Contact Details:
800 BOSTON TURNPIKE
SHREWSBURY
MA
01545
United States of America
Tel:508 936 4200
Fax:
Email:
WWW:

www.tranxenogen.com/




Loading...

Recent Publications by TranXenoGen:

A potential antitumor peptide therapeutic derived from antineoplastic urinary protein.
New therapies in cancer treatment are focusing on multifaceted approaches...
19th February, 2005
TranXenoGen Inc., Technology Development, 800 Boston Turnpike, Shrewsbury, Peptides. 2004 Apr;25(4):543-9.
DOI Direct Link

Press Releases on TranXenoGen:

BioPortfolio Logo
PwC BioScience Index & Share League September - October 2002 1st November, 2002 Pwc
  PwC BioScience Index & Share League September - October 2002 The PwC BioScience Index highlights the performance of UK bioscience companies

TranXenoGen Patents:

US Patent No.Title
7326679 Anticancer peptide compositions
6753457 Nuclear reprogramming using cytoplasmic extract

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 288 times since April 2007, the link to the organisation's website has been followed 73 times

Recent Search Terms used to find this page: tranxenogen | tranxenogen | tranxenogen | .

Search for more companies in SHREWSBURY

Search for more companies in MA



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for TranXenoGen

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.